These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15270804)

  • 1. Thiazolidinediones and congestive heart failure--exacerbation or new onset of left ventricular dysfunction?
    Srivastava PM; Calafiore P; MacIsaac RJ; Hare DL; Jerums G; Burrell LM
    Diabet Med; 2004 Aug; 21(8):945-50. PubMed ID: 15270804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
    Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
    Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
    Fonarow GC
    Am Heart J; 2004 Oct; 148(4):551-8. PubMed ID: 15459582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.
    Toprani A; Fonseca V
    Diabetes Obes Metab; 2011 Mar; 13(3):276-80. PubMed ID: 21205120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.
    Dargie HJ; Hildebrandt PR; Riegger GA; McMurray JJ; McMorn SO; Roberts JN; Zambanini A; Wilding JP
    J Am Coll Cardiol; 2007 Apr; 49(16):1696-704. PubMed ID: 17448371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
    Patel C; Wyne KL; McGuire DK
    Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations for management of fluid dynamic issues associated with thiazolidinediones.
    Hollenberg NK
    Am J Med; 2003 Dec; 115 Suppl 8A():111S-115S. PubMed ID: 14678876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
    Strowig SM; Raskin P
    Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
    Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
    Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial.
    Das SR; Drazner MH; Yancy CW; Stevenson LW; Gersh BJ; Dries DL
    Am Heart J; 2004 Nov; 148(5):883-8. PubMed ID: 15523322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones in type 2 diabetes--have they lived up to expectations?
    Bhansali A; Modi P
    J Indian Med Assoc; 2005 Jun; 103(6):343-6. PubMed ID: 16225162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sudden cardiovascular death following myocardial infarction: the importance of left ventricular systolic dysfunction and congestive heart failure.
    Abildstrom SZ; Ottesen MM; Rask-Madsen C; Andersen PK; Rosthøj S; Torp-Pedersen C; Køber L
    Int J Cardiol; 2005 Sep; 104(2):184-9. PubMed ID: 16168812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.